Our Services
Others
- DFPP
- Shockwave
- IV Drip
Based on the available clinical history, the medical team considers this pediatric case to represent an integrative management approach combining structured neurodevelopmental rehabilitation with supportive biological therapies for Autism Spectrum Disorder (ASD). The child’s clinical course involves a documented baseline of mild-to-moderate functional impact, a continuous program of occupational therapy (OT) targeting attention, fine motor control, and social engagement, alongside complementary supportive cell therapy protocols.
According to baseline evaluations using the Autism Treatment Evaluation Checklist (ATEC), the initial score was recorded at 58/179, consistent with mild-to-moderate functional impact. Clinical observation noted key strengths in motivation, responsiveness to visual and gesture prompts, and static/dynamic balance, alongside developmental challenges in sustained unprompted attention (limited to 4–5 minutes), handwriting consistency, cutting accuracy, and turn-taking in structured settings. Structured occupational therapy was initiated as the primary therapeutic foundation.
As part of a comprehensive care strategy, the family, in consultation with their multidisciplinary physicians, elected to incorporate supportive intravenous cell therapy alongside metabolic micronutrient infusions in parallel with ongoing occupational therapy.
In a subsequent phase, the family pursued an advanced course combining systemic administration with specialized hospital-based delivery under image guidance, accompanied by intensified occupational therapy. Comprehensive informed consent, addressing the investigational status of cellular therapies in neurodevelopmental conditions and standard procedural considerations, was documented prior to administration.
Following the integrative program, the medical team and occupational therapists observed measurable functional progress, including independent sorting, accurate multi-color pattern threading, successful two-choice discrimination, improved postural balance, and an age-appropriate pencil grasp. Because structured occupational therapy ran continuously alongside biological support, these improvements reflect a multi-modal outcome and cannot be attributed solely to any individual intervention.
Continuous occupational therapy remains the primary evidence-based modality driving functional motor, sensory, and behavioral development. While cellular signaling therapies are being explored scientifically for their potential role in modulating systemic immune pathways and supporting tissue environments, they remain investigational for neurodevelopmental indications.
The medical team recommends scheduled longitudinal ATEC evaluations, ongoing multidisciplinary pediatric assessment, and objective behavioral tracking to monitor the child’s developmental milestones.
The medical team recommends evaluating attention, motor skills, and social engagement as distinct functional parameters:
Cell therapies in this context are documented purely as an adjunctive supportive protocol within an individualized care history. They are not positioned as a definitive treatment or stand-alone therapy for core neurodevelopmental features of ASD, nor do they replace standard developmental interventions.
Occupational therapy remains the core pillar of ongoing care. The medical team recommends:
The medical team emphasizes that pediatric neurodevelopmental progress is optimized through sustained, structured behavioral and occupational interventions. Where adjunctive metabolic or cell therapies are utilized as supportive measures, they must be approached with realistic expectations, full regulatory compliance, and seamless coordination with licensed rehabilitation specialists.